The effects of RAMPs upon cell signalling by Routledge, Sarah J. et al.
Accepted Manuscript
The effects of RAMPs upon cell signalling
Sarah J. Routledge, Graham Ladds, David R. Poyner
PII: S0303-7207(17)30198-3
DOI: 10.1016/j.mce.2017.03.033
Reference: MCE 9907
To appear in: Molecular and Cellular Endocrinology
Received Date: 29 July 2016
Revised Date: 1 February 2017
Accepted Date: 24 March 2017
Please cite this article as: Routledge, S.J., Ladds, G., Poyner, D.R., The effects of RAMPs upon cell
signalling, Molecular and Cellular Endocrinology (2017), doi: 10.1016/j.mce.2017.03.033.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
© 2017, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/ 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
The effects of RAMPs upon cell signalling 
Sarah J Routledge1*, Graham Ladds1 and David R Poyner2   
 
1Department of Pharmacology, University of Cambridge, Cambridge  
CB2 1PD, United Kingdom 
 
2School of Life and Health Sciences, Aston University, Aston Triangle, 
Birmingham B4 7ET, United Kingdom  
 
*Corresponding author; Sarah J Routledge, Department of Pharmacology, Tennis 
Court Road, Cambridge, CB2 1PD, United Kingdom; +44 1223 334028; 
sr760@cam.ac.uk 
 
Abstract 
G protein-coupled receptors (GPCRs) play a vital role in signal transduction. It is 
now clear that numerous other molecules within the cell and at the cell surface 
interact with GPCRs to modulate their signalling properties. Receptor activity 
modifying proteins (RAMPs) are a group of single transmembrane domain 
proteins which have been predominantly demonstrated to interact with Family B 
GPCRs, but interactions with Family A and C receptors have recently begun to 
emerge. These interactions can influence cell surface expression, ligand binding 
preferences and G protein-coupling, thus modulating GPCR signal transduction. 
There is still a great deal of research to be conducted into the effects of RAMPs 
on GPCR signalling; their effects upon Family B GPCRs are still not fully 
documented, in addition to their potential interactions with Family A and C 
GPCRs. New interactions could have a significant impact on the development of 
therapeutics 
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Abbreviations 
AM, adrenomedullin; AMY, amylin; CaSR, calcium-sensing receptor, CGRP, 
calcitonin gene-related peptide; CHO, chinese hamster ovary; CLR, calcitonin 
receptor-like receptor; CT, calcitonin; CTR, calcitonin receptor; CRF, 
corticotrophin releasing factor; ECD, extracellular domain; ECL, extracellular 
loops; GCGR, glucagon receptor; GLP, glucagon-like peptide; GLP, GLP2R, 
glucagon-like peptide receptor 2; GPCR, G protein-coupled receptor; GPR30, G 
protein coupled estrogen receptor 1; GRKs, G protein-coupled receptor kinases; h, 
human; HEK, human embryonic kidney; m, mouse; NHERF-1, Na+/H+ exchanger 
regulatory factor-1;  PTX, pertussis toxin; PTH, parathyroid hormone; PTHR, 
parathyroid hormone receptor; PTHrP, parathyroid hormone related peptide; r, 
rat; RAMP, receptor activity modifying protein; s, salmon; VPAC, vasoactive 
intestinal peptide. 
 
1. Introduction 
In order to communicate and respond to their surrounding environment, cells 
utilise a vast array of signalling molecules ranging from neurotransmitters, 
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photons of light, lipids and hormones. Signals from many of these molecules are 
transduced by G protein-coupled receptors (GPCRs) which comprise the largest 
family of membrane proteins, with more than 800 of these seven 
transmembrane domain receptors now identified in the human genome[1]. As 
such, these receptors play a crucial role in mediating most physiological 
responses and are implicated in many disease states, making them valuable 
targets for drug development.  
  
In the classical model, upon receptor activation, GPCRs undergo a 
conformational change and activate an associated heterotrimeric G protein. GDP 
is exchanged for GTP on the Gα subunit, which dissociates from the βγ subunit. 
These liberated subunits then activate downstream effector molecules such as 
adenylyl cyclase and phospholipase C, resulting in stimulation or inhibition of an 
intricate web of signalling pathways within the cell to control processes 
including transcription, translation and metabolism [2, 3](Fig. 1). There are 16 
known Gα subunits, 5β and 12γ in humans, with the potential of hundreds of 
combinations[4]. In addition, there are thought to be G protein-independent 
signalling pathways activated by GPCRs[2] such as through β arrestins[5] and G 
protein-coupled receptor kinases (GRKs)[6]. 
 
GPCRs are much more complex than first envisioned; they were initially thought 
to behave like switches, with an inactive state and no signalling, or an active 
state initiating a signalling cascade. It is now clear that GPCRs occupy numerous 
conformations, which are associated with the activation of a range of signalling 
pathways. These conformations are stabilised by ligands, therefore certain 
agonists bias the receptor for a particular pathway or combination of pathways 
in comparison to another[3]. Complicating this system further, many GPCRs have 
been shown to interact with additional components[7]. Allosteric modulators 
bind to the receptors at a different location to the orthosteric ligand binding site. 
This further influences the pharmacology by altering orthosteric ligand affinity 
or efficacy, and in some cases may themselves act as allosteric agonists or 
antagonists[8, 9]. 
 
One such group of proteins that can have a significant impact upon GPCR 
location, ligand binding and signalling are the receptor activity modifying 
proteins (RAMPs), which were first identified through research into possible 
CGRP (calcitonin gene-related peptide) receptors.  One of the candidates, the 
then orphan Family B GPCR calcitonin receptor-like receptor (CLR), was difficult 
to study and responses to CGRP only appeared to occur in HEK293T cells and not 
others such as COS7 cells lines[10]. This information suggested the requirement 
of another component for a functional receptor, which was present in HEKs.  The 
elusive component was discovered 1998, when McLatchie et al injected Xenopus 
oocytes with the cDNA of SK-N-MC cells, which contain endogenous CGRP 
receptors.  They identified a population of cells with larger responses to CGRP 
and isolated the cDNA of a 148 amino acid single-pass membrane protein, which 
they named RAMP1[11]. Upon co-expression of CLR with RAMP1 in cells that did 
not contain endogenous CGRP receptors, a response to CGRP was observed  
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Figure 1. Signalling pathways of GPCRs. 
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equivalent to that seen in SK-N-MCs. Further investigation demonstrated that 
RAMP1 was required to transport CLR to the cell surface in order to form a 
functional receptor able to become bound and activated by CGRP[11]. Database 
searches identified two RAMP-like proteins named RAMP2 and RAMP3 with 
31% homology to one another. RAMP2 and RAMP3 were found to form the 
adrenomedullin 1 and 2 receptors (AM1R, AM2R) together with CLR[11, 12]. The 
RAMPs by themselves, like CLR, show only poor cell surface expression; however 
the RAMP/CLR heterodimers are efficiently trafficked to the outside of the cell. 
 
The interactions of the RAMPs with CLR and calcitonin receptor (CTR) are now 
well studied, providing us with better insight into the role of these accessory 
proteins[13]. It is now known that RAMPs can interact with some GPCRs to alter 
the pharmacology of the receptors by allosterically affecting the structure, 
altering ligand specificity and pharmacology, and in trafficking certain receptors. 
Several Family B receptors have now been shown to interact with the RAMPs, in 
addition to emerging interactions with GPCRs from Family A and C (summarised 
in Table 1). The consequences of these interactions in many cases are still 
unclear. Here we discuss research that has been conducted to investigate the 
role of RAMPs upon GPCR signalling; these findings are highlighted in Table 2. 
Other aspects of RAMPs have been recently reviewed elsewhere[14]. 
 
 
2. RAMP interactions with Family B GPCRs 
 
2.1 CLR 
The role of RAMPs in translocating CLR to the cell surface have been described 
above; it should further be noted that CLR by itself appears to be unable to bind 
with appreciable affinity any of the endogenous peptide ligands within the 
CGRP/calcitonin family. Two recent studies have cast some light on how RAMPs 
can influence peptide binding to CLR. Crystal structures of the extracellular 
domain (ECD) of CLR in combination with either the ECD of RAMP1 and a CGRP 
analogue or RAMP2 and an adrenomedullin (AM) fragment show that the RAMPs 
interact with the C-terminal residue of the peptide (F37-amide for CGRP, Y52-
amide for AM). For CGRP, F37 contacts W84 of RAMP1. (Fig. 2a). In RAMP2, the 
equivalent residue, F111 cannot make the necessary contact but instead there is 
an interaction with E101and Y52 of AM (Fig. 2b). In RAMP1, the equivalent of 
E101, W74, fails to contact CGRP.There are no further direct contacts between 
either peptide and the RAMPs. Instead the peptides have turn structures, not 
seen in other peptide ligands for family B GPCRs which contact CLR. There is 
evidence for some small but potentially significant RAMP-dependant shifts in the 
conformation of the contact residues on CLR, suggesting that the RAMPs act in 
part by allostery[15]. 
 
The RAMPs also seem to exert an effect on the extracellular loops (ECLs) of CLR. 
This has been investigated by mutagenesis; for each RAMP a different set of 
residues within the ECLs appear to be important. On the basis of molecular 
modelling, it has been suggested that RAMP-induced conformational changes in 
ECL3 may be particularly important[16]. 
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Table 1: Summary of known RAMP interactions with GPCRs 
 
 GPCR RAMP 
interaction 
partner 
Required for/ enhances 
receptor trafficking 
Influences peptide binding 
affinity 
Modulates signalling 
RAMP1 RAMP2 RAMP3 RAMP1 RAMP2 RAMP3 RAMP1 RAMP2 RAMP3 
CaSR RAMPS 1 and 3 X  X    X   
CLR RAMPS ,  and  X X X X X X X X X 
CTR RAMPS ,  and     X X X X  X 
CRF1R RAMP 2  X      X  
Glucagon RAMP 2     X   X  
GPR30 RAMP 3   X       
GLP2R RAMPS ,  and        X X X 
PTHR1 RAMP 2          
PTHR2 RAMP 3          
Secretin RAMP 3   X       
VPAC1 RAMPS ,  and         X  
VPAC2 RAMPS ,  and        X X  
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Table 2: RAMP modulation of GPCR signalling 
 
GPCR Family Agonists 
investigated 
G-proteins 
modulated 
by RAMPs 
RAMP 
interaction 
Effect upon signalling Other effects Refs 
GPR30 or 
GPER 
A Estrogen 
Tamoxifen 
G-1 
 RAMP3 Unknown Trafficking to cell surface [17, 18] 
CLR 
 
 
B CGRP 
AM1 
AM2 
Gαs, Gαi/o RAMP1 
RAMP2 
RAMP3 
RAMP1 promotes Gαs 
coupling of CGRP and Gαi 
coupling of AM and AM2. 
RAMP2 promotes Gαs 
coupling of AM. 
Confer ability to bind 
endogenous peptide 
ligands. Traffic receptor to 
the cell surface. 
RAMP3 decreases CLR 
internalisation. 
[19-21] 
CTR B Calcitonin 
Amylin 
CGRP 
Gαs, Gαq RAMP1 
RAMP2 
RAMP3 
RAMPs 1 and 3 increase 
Gαs coupling relative to 
Gαq and erk activation 
Enhance affinity for amylin 
and CGRP 
[22-26] 
CRF1R B CRF 
Urocortin 
Sauvagine 
Gαi/o, Gαq, 
Gα12/13 
RAMP2 No effect with Gαs. 
Enhanced basal and Emax 
with Gαi/o. 
Enhanced Emax with Gq. 
Enhanced agonist potency 
with Gα12/13 
Enhanced Ca2+ signalling 
with CRF and urocortin 
but not sauvagine. 
Enhanced trafficking to cell 
surface 
[27] 
Glucagon B Glucagon 
GLP1 
Oxyntomodulin 
Gαs, Gαi RAMP2 Reduced coupling to Gαi 
when activated by 
glucagon but not 
Binding of GLP-1 abolished [28-30] 
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oxyntomodulin. 
Enhanced Gαs coupling 
with oxyntomodulin 
GLP2R B GLP2 Gαs RAMP1 
RAMP2 
RAMP3 
RAMPs may alter basal 
signalling. 
 Unpublish
ed data 
PTH1 B   RAMP2 Not determined  [31] 
PTH2 B   RAMP3 Not determined  [31] 
Secretin B Secretin  RAMP3 No effect on cAMP, 
ERK1/2 phosphorylation, 
intracellular Ca2+ or 
internalization 
Trafficking [32] 
VPAC1 B VIP 
 
Possible 
Gαq 
coupling 
RAMP1 
RAMP2 
RAMP3 
RAMP2 enhances Emax for 
inositol phosphate 
production  
 [31] 
VPAC2 B VIP Gαi/o 
 
RAMP1 
RAMP2 
RAMP3 
RAMP 1and 2 enhanced  
basal coupling to Gαi/o 
and VIP potency 
 [27] 
Calcium 
sensing 
C Cinacelcet, 
neomycin 
Possible 
Gαq 
coupling 
RAMP1  
RAMP3 
RAMP1 may enhance Ca2+ 
signalling. 
Enhanced trafficking to cell 
surface.  
[33, 34] 
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Figure 2. Structure of ligand-bound RAMP-CLR complexes. (a) RAMP1/CLR (white) 
with CGRP27-37 [D31,P34,F35] (blue) bound (4RWG); (b) RAMP2/CLR (white) with AM22-52 (green) 
(4RWF). The key residues involved in RAMP/ligand interactions are shown. 
b) 
E101 
Y52 
a) 
W84 
F37 
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Little work has been done to investigate if RAMPs influence G protein selectivity 
of CLR. However, in both HEK293 cells and a model yeast system, they alter 
Gαs/Gαi/ Gαq coupling in a ligand-dependent manner[21]. It has been 
demonstrated that RAMP3 can interact with Na+/H+ exchanger regulatory 
factor-1 (NHERF-1) and this prevents receptor internalisation. This remains the 
only detailed study to investigate the effect of RAMPs on receptor 
internalisation[20].  
 
2.2 CTR 
The CTR was first cloned in 1991[35], and is known to have several isoforms 
with distinct pharmacology and signalling properties [24, 36, 37]. The most 
commonly expressed splice variant has a 16 amino acid insert in the first 
intracellular loop either present (denoted CTb receptor) or absent (denoted the 
CTa receptor)[24].  Differences in these two isoforms include reduced 
internalization in addition to reduced Gs and Gq signalling of the CTb 
isoform[24]. Activation of CTRs leads to effects in the bone, CNS, gastrointestinal 
and reproductive systems[36].   
 
Amylin is a peptide with substantial homology to CT, CGRP and adrenomedullin. 
Levels of amylin in circulation increase upon eating and physiological effects 
include the inhibition of glucagon secretion, gastric emptying and food 
consumption[22]. Two groups discovered that the CTR interacts with the RAMPs 
to form a receptor for amylin[22, 38]. In the most comprehensive study, it was 
found that COS-7 cells expressing the CTa receptor isoform in association with 
RAMP1 or RAMP3 led to formation receptors for amylin with differing 
affinities[22], and later found that RAMP2 together with CT also resulted in an 
amylin receptor distinct from the RAMP1 and RAMP3 phenotypes, although 
these findings were influenced by the cell line and also the isoform of CTR 
expressed[23]. All three RAMPs couple to CTa and CTb, however creation of an 
AMY receptor with RAMP2 appears to favour the CTb variant[23, 24]. Unlike 
CLR, CTR does not require association with RAMPs for cell surface 
expression[22].  
 
It has now been demonstrated that the AMY1 receptor has highest affinity for 
salmon CT (sCT), followed by amylin and CGRP and low affinity for mammalian 
CT. The AMY2 and 3 receptors parallel this pharmacology with lower affinities 
for CGRP[39]. Since the CTR signals through Gs and Gq, it is assumed that the 
AMY receptors also couple to these G proteins, although coupling of G proteins 
with the CTb isoforms may be reduced[39].  
 
Several studies have provided mechanistic insight into how RAMPs alter ligand 
binding to CTR. An extensive mutagenesis screen of the ECD of CTR[40] 
suggested that the RAMPs had allosteric actions; on the basis of molecular 
modelling, it was suggested that the RAMPs might influence the dynamics of loop 
5 and residues immediately C-terminal of the CTR. Similarly, based on the 
structure of the ECD of the CTR in complex with a salmon calcitonin analogue, it 
has been suggested that the RAMPs change the orientation of R126 in loop 5 of 
CTR to enhance the affinity of the receptor for amylin[41]. The structure 
suggests that the C-terminus of calcitonin is unlikely to be able to interact with 
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the RAMPs. In view of the key role of the C-terminal residues of CGRP and AM, it 
is surprising that the equivalent residue of amylin, Y37, is of little importance for 
binding[42]. This raises questions as to the importance of direct RAMP contacts 
with amylin. It is also interesting that RAMPs enhance the affinity of a CTR/CLR 
orthologue from Branchiostoma floridae to bind its calcitonin/CGRP 
orthologues[43]. Whilst the authors of this study interpret their results in terms 
of the RAMPs enhancing cell surface expression of the CTR/CLR orthologue, the 
peptides which it binds appear much closer to calcitonin than CGRP at their C-
termini and so it is not clear that they make direct contact with the RAMPs. If this 
is correct, it would further strengthen the case for an allosteric role of RAMPs. 
 
A study into the role of the C-terminus of the RAMPs upon interaction of the 
CTRa isoform was conducted by Sexton et al in 2006, and was the first study to 
illustrate that the C-terminus is involved in signalling. Chimeric RAMPs with C-
terminal domains swapped were created; RAMP1 with the C-terminus of RAMP2, 
and RAMP2 with the C-terminus of RAMP1. CTRa co-expressed with chimeras 
containing a RAMP1 C-terminus exhibited similar cAMP signalling profiles to 
RAMP1 and CTRa with high affinity for hCT, hCGRP and rAMY (rat amylin), 
despite the RAMP2-CTRa receptor having lower affinities for CGRP[44].  
 
The RAMP2 C-terminus-containing chimeras also had similar signalling profiles 
to RAMP2 and CTRa [44]. These findings suggested that while the N-terminus 
contributes to the peptide binding site and the TMD to receptor-RAMP stability, 
the C-terminus, although relatively short at 10 amino acids, is involved in 
determining the signalling profile of amylin receptors generated from the CTR. 
Deletion of a large proportion of the C-terminus results in a loss of high affinity 
amylin receptors[25]. Following on from this, RAMP1 and RAMP3 were found to 
significantly increase the potency of AMY at AMY1 and AMY3 receptors via Gs 
mediated cAMP production, but only slight increases in Ca2+ and ERK1/2 
activation were observed when compared to CTRa without RAMPs. This implies 
that RAMPs affect G protein-coupling efficiency of the AMY receptors, and induce 
more efficient coupling to Gαs than other G proteins[26]. 
 
 
2.3 CRF1R 
There are two subtypes of corticotrophin releasing factor (CRF) receptor in 
humans. When activated, these receptors predominantly signal through Gs and 
are involved in the synthesis and release of adrenocorticotropic hormone 
(ACTH) and β-endorphins from pituitary glands. They have been implicated in 
stress and anxiety-related endocrine responses[45]. A RAMP2 interaction has 
been demonstrated for the type 1 receptor (CFR1). A study by Wootten et al 
demonstrated that this interaction leads to the improved trafficking of the 
receptor to the cell surface, as well as affecting signalling[27]. There was no 
effect of RAMP2 to coupling of the receptor to Gαs upon challenge with the 
agonists CRF, urocortin 1 and sauvigne. However, GTPγS binding revealed 
improved coupling of CRF1 to Gαi/o/t/z, Gαq/11 and Gα12/13 in the presence 
of RAMP2. Improvements in G protein coupling were not found to be a result of 
enhanced trafficking of the receptor to the cell surface. RAMP2 interactions 
resulted in greater basal coupling of CRF1 to Gi/o/t/z and a higher maximum 
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response when stimulated by CRF. Improved Gq/11 coupling led to an increase 
in maximum Ca2+ with both CRF and urocortin 1, but not sauvagine. This 
demonstrates that the signalling effects of RAMP-receptor interactions may be 
ligand dependent. Investigations with inhibitors suggested that the elevated Ca2+ 
in the presence of RAMP2 came from extracellular sources in addition to 
intracellular pools, whereas the CRF1 alone mobilized intracellular stores[27]. 
 
 
2.4 Glucagon receptor 
Glucagon is a peptide involved in blood glucose regulation and generally opposes 
the effects of insulin. Activation of its receptor leads to conversion of glycogen to 
glucose in the liver where it is released into the blood to maintain glucose 
levels[46]. The glucagon receptor (GCGR) couples to Gαs, Gαi/o and Gαq/11[28-
30], and has been shown to traffic RAMP2 to the cell surface[28, 31]. Further 
studies demonstrated that upon co-expression of its receptor with RAMP2, 
glucagon was more potent and Emax was increased[28]. This was not due to 
enhanced cell surface expression of GCGR, or an effect upon ligand affinity.  A 
yeast system developed to allow coupling of human GPCRs and chimeric G 
proteins to activate an endogenous yeast-mating pathway[47] was used to 
investigate coupling of GCGR to Gαs and Gαi. Activation of individual pathways 
can be determined in relation to yeast cell growth, and findings suggested that 
co-expression of RAMP2 with the GCGR in the GPA1/Gαs containing strain 
resulted in an increase in the maximum response and potency of glucagon. When 
expressed in the GPA1/Gαi expressing strain, RAMP2 led to a reduction in 
response. In HEK293 cells, there was no significant change was observed in Gαs 
activation, however Gi coupling was significantly decreased, thereby elevating 
the cAMP response. PTX treatment of cells to prevent activation of Gαi resulted 
in an increase in Gαs coupling with GCGR alone, but did not affect the maximum 
cAMP produced when coexpressed with RAMP2. These results suggest that 
RAMP2 reduced coupling of GCGR to Gαi, and uncovers an important role for the 
RAMPs in modulating G protein coupling and cell signalling[28].  
 
Another significant finding by this study is that this is effect ligand specific. 
Oxyntomodulin is a less potent agonist at the GCGR than its cognate ligand, and 
RAMP2 co-expression also led to increased potency on cAMP production without 
affecting the binding affinity. Here, studies with pertussis toxin (PTX) and in 
yeast suggest the effects are due to augmented coupling of Gs, rather than 
reduced coupling to Gαi[28].  
 
In addition, RAMP2 was capable of abolishing binding of GLP-1, which is a partial 
agonist at the GCGR. Liraglutide, a GLP-1 analogue and weak GCGR agonist used 
in diabetes treatment, was also unable to bind the receptor in the presence of 
RAMP2. This effect is not seen at the GLP-1 receptor, where GLP-1 binding and 
activation is not affected by RAMPs, and is therefore receptor-specific[28, 29]. 
 
 
2.5 GLP2R 
Glucagon-like peptide 2 (GLP-2) is a peptide derived from proglucagon and 
secreted from intestinal enteroendocrine L cells and has a 40% similarity to 
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other proglucagon-derived peptides, GLP-1 and glucagon[48]. Activation of the 
GLP-2 receptor (GLP-2R) by its 33 amino acid peptide causes signalling through 
Gαs, leading to crypt cell proliferation in the small intestine, and has been found 
to improve nutrient absorption in patients with short bowel syndrome and to 
regulate blood glucose[48, 49]. 
 
The GLP-2R had previously been investigated for RAMP interaction, but none 
had been detected[31]. We have recently investigated the GLP2R for interaction 
with the RAMPs by cell surface ELISA in HEK293Ts and our preliminary data 
suggests each of the RAMPs were detected at the cell surface upon coexpression 
with GLP2-R. The data also suggest that the RAMPs change either the basal or 
maximum stimulation of cAMP. 
 
 
2.6 PTHR1 and PTHR2 
Parathyroid hormone (PTH) regulates blood calcium levels as well as mineral 
ions and is secreted from the parathyroid cells in response to low extracellular 
Ca2+ and elevated extracellular phosphate[50, 51]. It has two receptors, PTHR1 
and PTHR2. Another similar peptide, parathyroid hormone related peptide 
(PTHrP) is also able to activate PTHR1, but not PTHR2[51]. PTHrP is normally 
involved in lactation where it promotes calcium mobilisation from bone, and in 
long bone development. Secretion is increased in tumours causing a rise in 
serum calcium, resulting in development of humoral hypercalcemia malignancy 
syndrome[51]. 
 
The study by Christopolous et al investigated cell surface expression of the 
RAMPs upon coexpression with the PTHRs for the first time.  An interaction was 
observed with PTHR1 and RAMP2 and with PTHR2 and RAMP3[31], however 
the consequences of these interactions are currently unknown. 
 
2.7 Secretin 
The secretin receptor was the first member of the Family B GPCRs to be cloned, 
and as such represents the model receptor for the family[52]. It was first cloned 
by Ishihara et al in 1991[53], and its biological roles include bile stimulation, 
gastric pepsin secretion and release of insulin from the pancreas upon intake of 
glucose[53, 54]. Secretin receptors are expressed in the brain, stomach, 
pancreas, kidneys and the liver, and are thought to couple to Gαs and Gαq[54, 
55]. 
 
Harikumar et al demonstrated an interaction of the secretin receptor and RAMP3 
for the first time in 2009[32]. The receptor is normally able to traffic to the cell 
surface alone, however RAMP3 restored this ability to a mutant receptor 
(G241C) unable to traffic, suggesting a role for RAMP3 as a chaperone whether 
required for normal expression or not[32]. Investigation into possible effects of 
RAMP3 upon signalling of the secretin receptor were conducted, however no 
changes were observed to cAMP, ERK1/2 phosphorylation, intracellular Ca2+ or 
internalization of the receptor. In addition, RAMP3 appeared to have no effect 
upon binding of secretin to its receptor, and unsurprisingly, no interaction was 
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observed with the N-terminus of the receptor with RAMP3. Instead, interaction 
sites were found to be with TM6 and TM7. Interestingly, the study discovered 
that RAMP3 interacted with a homodimer of the secretin receptor, and that the 
receptor competed for RAMP3 with CLR, thus reducing functional CLR-RAMP3 
generated adrenomedullin receptors at the cell surface[32]. 
 
 
2.8 VPAC1R 
Vasoactive Intestinal Peptide activation of VPAC1 leads to growth and 
development and is involved in immune response[56]. The successful cloning of 
VPAC1R from rat lung cDNA library was published in 1992[57]. VPAC1R has 
been reported to couple to Gαs, Gαi/o and Gαq[58] as well as numerous other 
second messengers such as tyrosine kinases, calcium channels, MAPK and RhoA 
GTPases[59].  Stimulation of VPAC1R with VIP predominantly stimulates cAMP 
production, with lower levels of phosphoinositide (PI) hydrolysis, an indication 
of PLC activation and Gαq coupling[27, 31, 59]. Increases in calcium levels have 
also been observed [58]. Christopoulos et al observed trafficking to the cell 
surface of all three RAMPs upon coexpression with VPAC1R [31].  Following 
upon these findings, they discovered that the RAMPs did not affect ligand 
binding, nor did they alter expression levels of the VPAC1R at the cell 
surface[31].  Upon further investigation into possible effects upon cell signalling, 
it was found that the RAMPs did not affect cAMP production, but RAMP2 
significantly enhanced the hydrolysis of PI[31]. They suggested that RAMP2 may 
improve the signalling efficiency of the receptor.  
 
 
2.9 VPAC2R 
The VPAC2R was first cloned in 1993 by Lutz et al from a rat pituitary cDNA 
library[60]. Initial investigations for interaction of the VPAC2R in HEK293 cells 
did not reveal any interactions[31], but a later study by Wootten et al 
demonstrated trafficking of all three RAMPs to the cell surface when co-
transfected with VCAP2R in HEK293S and CHO-K1 cells, with larger effects seen 
in the former[27]. These findings highlight the variations between cell lines and 
the authors noted that the expression levels of RAMPs in each cell type should be 
considered when interpreting data.  
 
While the study did not find any significant changes to binding of VPAC2 agonists 
VIP, BAY55-9837, PCAP-27 and PHM-27 in the presence of the RAMPs, G protein 
coupling, however, was affected. GTPγS binding assays demonstrated that 
although there were no RAMP-mediated changes to Gαs coupling when 
stimulated with VIP, there were significant increases in basal coupling to Gαi/o 
in HEK293S and CHO-K1 cells with RAMP1 and RAMP2 co-transfection[27]. In 
addition, VIP appeared to increase the potency of this coupling with RAMP1. No 
change to coupling with Gαq/11 or Gα12/13 was observed for VPAC2R alone or 
with any of the RAMPs[27]. 
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2.10 GPR30 
G protein coupled estrogen receptor 1, or GPR30, is expressed in the human and 
rodent heart and activation by estradiol, a form of estrogen, mediates pleiotropic 
function in the cardiovascular system in addition to the endocrine, immune and CNS 
and may be involved in cardioprotection[17]. Lenhart et al recently described for 
the first time the interaction of RAMP3 with GPR30[17], which they theorized 
could interact due to evidence that estrogen regulates Ramp3 gene expression. 
They found that RAMP3 increases GPR30 expression at the cell surface[61]. 
 
At present, there is currently no known effect of RAMPs upon the signalling 
profile of this receptor. 
 
 
2.11 Calcium-sensing receptor 
The calcium-sensing receptor (CaSR) is a Family C GPCR that is able to bind Ca2+ 
and is therefore involved in calcium homeostasis. It is also capable of binding 
Mg2+, Zn2+ and Ni2+ in addition to antibiotics like neomycin[34]. This receptor is 
also involved in PTH and CT secretion[33, 34]. It is capable of coupling to several 
G proteins including Gαs, Gαi, Gαq, and Gα12/13[34]. 
 
It was first shown by Bouschet et al to interact with RAMPs 1 and 3 but not 
RAMP2, making this the first known interaction between a RAMP and a Family C 
GPCR[62]. This has now been demonstrated in both transfected cell lines and 
endogenously expressing cells[34, 62, 63]. RAMP1 and 3 interactions are a 
requirement in order to traffic the receptor to the cell surface[34, 62, 63]. In 
addition, RAMP3 association has been shown to lead to further glycosylation of 
CaSR[62].  
Expanding upon this research, Desai et al demonstrated that RAMP1 also played 
a role in the signalling of the receptor. Knockdown of RAMP1 expression by 
siRNA in medullary thyroid carcinoma TT cells, endogenously expressing RAMP1 
only, resulted in a 50% reduction in Ca2+ signalling by Cinacelcet (a CaSR 
allosteric modulator) and neomycin (a CaSR agonist)[34]. Stoichiometric 
analysis revealed there to be approximately 1.6 times more RAMP3 associated 
with CaSR than with RAMP1; the authors suggested that receptors may interact 
with more than one molecule of RAMP[34], however, this has yet to be fully 
explored. 
 
2.12 The role of RAMPs in pathophysiology 
The upregulation of RAMPs and the modulation of receptor response to ligands, 
in particular to AM, are involved in numerous disease states and several studies 
have investigated knockout mice to better understand their role. In an 
investigation into skin wound healing, RAMP1 (-/-) mice displayed reduced 
wound-induced angiogenesis and lymphangiogenesis and their ability to heal 
wounds was decreased compared to WT mice [64]. RAMP2 (-/-) mice have been 
demonstrated to die in utero as a result of improper vascular development and 
edema, an outcome that is also observed in AM(-/-) mice [65]. Heterozygous 
RAMP2 (+/-) knockout acute and chronic cerebral ischemia models to 
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investigate cerebrovascular disease demonstrated greater upregulation of AM 
gene expression compared to WT mice after induction of infarction. This was 
thought to compensate for reduced RAMP2 expression[65]. The findings 
suggested a protective role for RAMP2 with the AM receptor complex by 
reducing oxidative stress, inflammation and restoring blood flow, thereby 
protecting against brain injury.  
 
RenTgMK mice, used to model cardiac hypertrophy and chronic hypertension 
where male mice have increased cardiac hypertrophy and reduced survival 
compared to females, were investigated in addition to RAMP3 (-/-) 
knockout[61]. An increase in AKT activation (a regulator of cardiomyocyte cell 
survival and apoptosis) was observed in male RenTgMK; RAMP 3 (-/-) mice 
when compared to female RenTgMK and RenTgMK; RAMP 3 (-/-) mice, with an 
associated increase in cardiac apoptosis. The males also exhibited significant 
depressed systosolic function and renal damage when compared to the females. 
In addition, female mouse hearts displayed increased Ramp3 gene expression 
during cardiovascular stress[61]. These findings suggest that there is a sex-
dependent role for RAMP3 as a cardioprotectant, linked to oestrogen-regulated 
Ramp3 gene expression [61]. A study on RAMP-receptor trafficking found that 
the interaction of the RAMP3 PDZ type 1 motif with NSFs (N-ethylmaleimide-
sensitive factor) promoted targeting of the CLR-RAMP3 complex for recycling 
after internalization upon agonist stimulation. The authors suggest that since 
RAMP3 expression is increased the myocardium of rats with chronic heart 
failure, this may then allow for improved recycling of AM receptors and 
therefore extend exposure to the protective effect of AM in this condition and 
others such as type 1 and 2 diabetes and chronic glomerulonephritis where AM 
is elevated[20]. 
 
 
3. Conclusions 
RAMPs modulate GPCRs in numerous ways. The simplest of these is by acting as 
molecular chaperones and this may have been the first function to appear in 
evolution[43] and is seen across Families A, B and C of GPCRs. However, beyond 
this, they can also modulate ligand binding and cell signalling. Although first 
characterised for their effects on conferring the ability of CLR to bind to its native 
peptide agonists, the most common effect across GPCRs seems to be modulation 
of cell signalling. These effects can manifest themselves as changes in agonist 
potency (without any change in affinity), the size of the maximum response and 
basal activity. Furthermore, the effects are frequently agonist-specific. These 
suggest that the RAMPs work by altering the conformation of the 
transmembrane domain of the GPCRs (Figure 3). The ECD of the RAMPs may 
influence the ECD of the GPCR and, through this, the transmembrane domain; for 
some Family B GPCRs, the ECD is an allosteric regulator of signalling[66]. There 
are also likely to be direct interactions of the RAMPs with the ECLs of the GPCRs, 
which will change alter the conformation of the transmembrane helices. The 
transmembrane domain of the RAMP must pack against the transmembrane 
helices of the GPCRs and this may alter either their conformation or their 
movements during receptor activation. Finally the C-termini of the RAMPs can 
interact with the intracellular loops of the GPCRs and possibly the G proteins 
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themselves. All these provide potential mechanisms allowing RAMPs to tune 
GPCR signalling. 
 
For the future, there is still significant work to document the full range of RAMP 
interactions with all of the Family B GPCRs. The recent work showing that 
RAMP1 can influence calcium signalling at the CaSR suggests that the effects on 
signal transduction may extend at least to Family C GPCRs. Very little work has 
been done to investigate the influence of RAMPs on β-arrestins or the interaction 
of other proteins with GPCRs, but the influence of RAMP3 on CLR internalisation 
illustrates that this may be significant[20]. The effects of RAMPs depend heavily 
on the cell line in which the receptor is expressed; the molecular basis for this is 
not clear but it implies that the physiological consequences of RAMP expression 
are crucially dependant on the cells in which they are expressed. If this is 
understood, then there is considerable potential to develop drugs that are 
targeted against specific RAMP/GPCR complexes.  
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Figure 3. Mechanisms of RAMP interactions
GPCR%
%
R
A
M
P
%
GPCR%
%
R
A
M
P
%
GPCR%
%
R
A
M
P
%
Gαi/o% Gαq/11%Gαs% Gα12/13%
%
R
A
M
P
%
GPCR%
Trafficking%
Ligand%specificity%
and%signalling%
DegradaBon%and%
recycling%
%
R
A
M
P
%
GPCR%
Endoplasmic%reBculum%
Endosome%
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Figure Legends 
 
Figure 1. Signalling pathways of GPCRs. 
 
Figure 2. Structure of ligand-bound RAMP-CLR complexes. (a) RAMP1/CLR 
(white) with CGRP27-37 [D31,P34,F35] (blue) bound (4RWG); (b) RAMP2/CLR 
(white) with AM22-52 (green) (4RWF). The key residues involved in RAMP/ligand 
interactions are shown. 
 
Figure 3. Mechanisms of RAMP interactions 
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Highlights 
 
• RAMPs have been shown to interact predominantly with Family B GPCRs, 
and recently with Family A and Family C GPCRs. 
• RAMPs enhance trafficking to the cell surface of several GPCRs 
• RAMPs can alter GPCR signalling including enhancing coupling to certain 
G-proteins. 
